Immunohistochemical study of MSI markers in breast cancer

Kuznetsova O.A.

Russian Medical Academy of Continuous Professional Education

ORCID: 0000-0002-9721-6355

Zavalishina L.E.

Russian Medical Academy of Continuous Professional Education

ORCID: 0000-0002-0677-7991

Andreeva Yu.Yu.

Russian Medical Academy of Continuous Professional Education

SPIN RSCI: 6504-2551
Scopus AuthorID: 8656328100
ORCID: 0000-0003-4749-6608

Vinogradov M.I.

Regional Clinical Oncology Dispensary

ORCID: 0000-0002-8173-6823

Shomova M.V.

Regional Clinical Oncology Dispensary

ORCID: 0000-0002-6235-0925

Frank G.A.

Russian Medical Academy of Continuous Professional Education

ORCID: 0000-0002-3719-5388

Immunohistochemical study of MSI markers in breast cancer

Authors:

Kuznetsova O.A., Zavalishina L.E., Andreeva Yu.Yu., Vinogradov M.I., Shomova M.V., Frank G.A.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2021;83(1): 12‑17

DOI: 10.17116/patol20218301112

Read: 5143 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kuznetsova OA, Zavalishina LE, Andreeva YuYu, Vinogradov MI, Shomova MV, Frank GA. Immunohistochemical study of MSI markers in breast cancer. Russian Journal of Archive of Pathology. 2021;83(1):12‑17. (In Russ.)
https://doi.org/10.17116/patol20218301112

Подписка 2025-2 (Russian Journal of Archive of Pathology)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To investigate the expression of microsatellite instability (MSI) markers, which is detected by an immunohistochemical technique, and to compare the expression with the PD-L1 status in luminal B, HER2-negative and triple-negative breast cancer.

MATERIAL AND METHODS

The investigation included tumors from 40 patients with triple-negative and luminal B, HER2-negative subtypes. Immunohistochemical study was performed using Ventana antibodies: anti-MLH1 (clone M1), anti-MSH2 (clone G219-1129), anti-PMS2 (clone A16-4), and anti-MSH6 (clone SP93). MSI was assessed according to the standard criteria.

RESULTS

The PD-L1-positive status was present in 14 (35%) of the 40 patients. Moreover, MSI-H was detected in only 1 (2.50%) case. The two-year survival rate was 87.5%; it should be noted that the median survival rate was not reached either in the study sample or in the groups divided according to PD-L1 and MSI statuses. The overall survival rate for patients with MSI was 75% (3/4).

CONCLUSION

The first comparative study of the expression of PD-L1 and immunohistochemical MSI markers, which has been conducted on a small sample, fails to draw unambiguous conclusions, but shows the need to investigate this phenomenon on large samples and by using genetic methods.

Keywords:

breast cancer

PD-L1

SP142

MSI

microsatellite instability

Authors:

Kuznetsova O.A.

Russian Medical Academy of Continuous Professional Education

ORCID: 0000-0002-9721-6355

Zavalishina L.E.

Russian Medical Academy of Continuous Professional Education

ORCID: 0000-0002-0677-7991

Andreeva Yu.Yu.

Russian Medical Academy of Continuous Professional Education

SPIN RSCI: 6504-2551
Scopus AuthorID: 8656328100
ORCID: 0000-0003-4749-6608

Vinogradov M.I.

Regional Clinical Oncology Dispensary

ORCID: 0000-0002-8173-6823

Shomova M.V.

Regional Clinical Oncology Dispensary

ORCID: 0000-0002-6235-0925

Frank G.A.

Russian Medical Academy of Continuous Professional Education

ORCID: 0000-0002-3719-5388

Contribution of Authors:

The concept and design of the study — G.A. Frank

Collection and processing of material — M.I. Vinogradov, O.A. Kuznetsova

Statistical processing — O.A. Kuznetsova

Text writing — L.E. Zavalishina, Yu.Yu. Andreeva

Editing — M.V. Shomova, Yu.Yu. Andreeva

Received:

28.10.2020

Accepted:

16.11.2020

Conflict of Interest :

The authors declare no conflict of interest.

List of references:

Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Henschel V, Molinero L, Chui SY, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet Oncol. 2020;21(1):44-59. https://doi.org/10.1016/S1470-2045(19)30689-8
Raez L, Santos E. Tumor type-agnostic treatment and the future of cancer therapy. Target Oncol. 2018;13(5):541-544. https://doi.org/10.1007/s11523-018-0593-y
Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. 2006;7(5):335-346. https://doi.org/10.1038/nrm1907
Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol. 2003;21(6):1174-1179. https://doi.org/10.1200/JCO.2003.04.060
Lamers M, Perrakis A, Enzlin J, Winterwerp H, de Wind N, Sixma T. The crystal structure of DNA mismatch repair protein MutS binding to a G×T mismatch. Nature. 2000;407(6805):711-717. https://doi.org/10.1038/35037523
Salem ME, Puccini A, Grothey A, Raghavan D, Goldberg RM, Xiu J, Korn WM, Weinberg BA, Hwang JJ, Shields AF, et al. Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers. Mol Cancer Res. 2018;16(5):805-812. https://doi.org/10.1158/1541-7786.MCR-17-0735
Viale G, Trapani D, Curigliano G. Mismatch repair deficiency as a predictive biomarker for immunotherapy efficacy. Biomed Res Int. 2017;2017:4719194. https://doi.org/10.1155/2017/4719194
Frank GA, Kuznetsova OA, Zavalishina LE, Andreeva YY, Moskvina LV. Study of the PDL1 status in breast cancer, by using the SP142 monoclonal antibody, and the prospects for determining treatment policy. Arkhiv patologii/Archive of Pathology. 2019;81(5):5-10. https://doi.org/10.17116/patol2019810515
Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O’Hear C, Fassò M, Molinero L, Schmid P.Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Ooncol. 2019;5(1):74-82. https://doi.org/10.1001/jamaoncol.2018.4224
Fusco N, Lopez G, Corti C, Pesenti C, Colapietro P, Ercoli G, Gaudioso G, Faversani A, Gambini D, Michelotti A, Despini L, Blundo C, Vaira V, Miozzo M, Ferrero S, Bosari S. Mismatch repair protein loss as a prognostic and predictive biomarker in breast cancers regardless of microsatellite instability. JNCI Cancer Spectr. 2018;2(4):pky056. https://doi.org/10.1093/jncics/pky056
Zang YS, Dai C, Xu X, Cai X, Wang G, Wei J, Wu A, Sun W, Jiao S, Xu Q. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer. Cancer Med. 2019;8(10):4699-4708. https://doi.org/10.1002/cam4.2381
Muenst S, Schaerli AR, Gao F, Däster S, Trella E, Droeser RA, Muraro MG, Zajac P, Zanetti R, Gillanders WE, Weber WP, Soysal SD. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2014;146(1):15-24. https://doi.org/10.1007/s10549-014-2988-5
Li Z, Dong P, Ren M, Song Y, Qian X, Yang Y, Li S, Zhang X, Liu F. PD-L1 expression is associated with tumor FOXP3+ regulatory T-cell infiltration of breast cancer and poor prognosis of patient. J Cancer. 2016;7(7):784. https://doi.org/10.7150/jca.14549
Beckers RK, Selinger CI, Vilain R, Madore J, Wilmott JS, Harvey K, Holliday A, Cooper CL, Robbins E, Gillett D, Kennedy CW, Gluch L, Carmalt H, Mak C, Warrier S, Gee HE, Chan C, McLean A, Walker E, McNeil CM, Beith JM, Swarbrick A, Scolyer RA, O’Toole SA. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology. 2016;69(1):25-34. https://doi.org/10.1111/his.12904
AiErken N, Shi HJ, Zhou Y, Shao N, Zhang J, Shi Y, Yuan ZY, Lin Y. High PD-L1 expression is closely associated with tumor-infiltrating lymphocytes and leads to good clinical outcomes in Chinese triple negative breast cancer patients. Int J Biol Sci. 2017;13(9):1172-1179. https://doi.org/10.7150/ijbs.20868
Kim A, Lee SJ, Kim YK, Park WY, Park DY, Kim JY, Lee CH, Gong G, Huh GY, Choi KU. Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. Sci Rep. 2017;7(1):11671. https://doi.org/10.1038/s41598-017-11905-7

Close metadata